Medical Cannabis for Knee Pain UK – Arthritis Guide

Medical Cannabis for Knee Pain in the UK: A Comprehensive Guide

Knee pain affects millions of people across the United Kingdom, whether from chronic arthritis, post-surgical complications, or injury. Recent changes in UK law have opened new treatment possibilities, including medical cannabis. This guide explores the evidence, access routes, and practical considerations for those considering this option.

Understanding Medical Cannabis in the UK

Medical cannabis became legal in the United Kingdom in November 2018, when it was reclassified from a Schedule 1 to a Schedule 2 controlled drug. This reclassification allowed registered healthcare professionals to prescribe cannabis-based medicinal products for patients where conventional treatments have proven ineffective or unsuitable.

It is crucial to understand that medical cannabis differs significantly from recreational cannabis. Medical products are standardised, quality-controlled, and contain specific ratios of cannabinoids—primarily cannabidiol (CBD) and tetrahydrocannabinol (THC). The focus is on therapeutic benefit rather than recreational effects.

Knee Pain from Arthritis

Arthritis represents one of the most common causes of chronic knee pain in the UK. Osteoarthritis affects over 8 million people, whilst rheumatoid arthritis impacts approximately 400,000. Both conditions involve inflammation, joint degradation, and persistent discomfort that significantly impairs quality of life.

Traditional treatments include NSAIDs, corticosteroid injections, and physiotherapy. However, some patients experience inadequate pain relief or cannot tolerate conventional medications due to side effects such as gastrointestinal issues or cardiovascular concerns.

Research suggests that cannabis may help arthritis through several mechanisms. CBD possesses anti-inflammatory properties, whilst THC may contribute analgesic effects. Studies indicate that cannabinoids interact with the endocannabinoid system, which plays a role in regulating pain and immune responses. A 2019 review published in the journal Cannabis and Cannabinoid Research noted that cannabis shows promise for arthritis-related pain management, though larger clinical trials are needed.

Post-Surgical Knee Pain

Knee surgery, whether arthroscopy, ACL reconstruction, or joint replacement, frequently results in acute and chronic post-operative pain. Whilst most patients recover well with conventional pain management, some experience prolonged pain lasting months or even years—a condition termed chronic post-surgical pain.

The opioid crisis has made best UK cannabis clinics increasingly cautious about long-term opioid use, leaving a treatment gap for patients with persistent surgical pain. Medical cannabis may offer an alternative or complementary approach. Anecdotal reports from patients suggest cannabis helps manage post-surgical inflammation and pain when other treatments plateau.

However, evidence specifically for post-surgical knee pain remains limited. Most research focuses on general post-operative pain rather than knee-specific applications. Prospective patients should discuss with their consultant whether medical cannabis might suit their particular surgical recovery situation.

Current Evidence Base

The evidence supporting medical cannabis for knee pain exists but remains moderate. The National Institute for Health and Care Excellence (NICE) has not issued specific guidance endorsing cannabis for arthritis or knee pain, reflecting the gaps in robust clinical data.

Published studies are often small-scale or conducted in other countries with different regulatory frameworks. A 2020 Cochrane review identified significant methodological limitations in cannabis pain research. Nevertheless, observational studies and patient reports suggest genuine therapeutic potential, particularly for inflammation-related pain.

Research continues internationally. Studies suggest that CBD primarily contributes anti-inflammatory benefits, whilst THC offers analgesia. The combination may be more effective than either component alone. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recognises the need for additional evidence, which is why access remains restricted and carefully monitored.

Topical versus Oral Administration

Medical cannabis for knee pain comes in several forms, each with distinct advantages and considerations.

Topical preparations include creams, oils, and patches applied directly to the knee. These offer several benefits: minimal systemic absorption, reduced side effects, and no intoxication. Patients appreciate the convenience and discretion of topical application. However, penetration varies, and some patients report inconsistent efficacy. Topicals work best for superficial inflammation rather than deep joint pain.

Oral medications encompass oils, capsules, and sprays taken by mouth. These deliver cannabinoids systemically, potentially addressing pain arising from deeper within the knee joint. Oral forms typically provide longer-lasting effects—between 6 to 12 hours—compared to topicals. The disadvantage is increased systemic effects and slower onset (30 minutes to 2 hours). Some patients experience drowsiness, dizziness, or appetite changes.

Many specialists recommend starting with lower-dose oral preparations or topicals, then adjusting based on response. Some patients benefit from combining both formats—topical for localised inflammation and oral for systemic pain management.

Accessing Medical Cannabis Prescriptions

Obtaining medical cannabis in the UK requires navigating a specific process. Only registered specialists can prescribe; general practitioners cannot. Eligible conditions—according to the MHRA—include chronic pain where conventional treatments have failed, epilepsy, multiple sclerosis, and nausea from chemotherapy.

Knee arthritis and post-surgical pain don’t appear on the standard eligible conditions list, yet specialists may prescribe unlicensed cannabis-based products under “special circumstances” if they deem conventional treatments inadequate. This discretionary approach means access varies significantly across NHS regions and private practice.

To access medical cannabis through the NHS, patients typically must:

• Have tried and failed conventional treatments (documented evidence essential)
• Be referred by their GP or consultant to a specialist experienced with cannabis prescribing
• Undergo assessment to confirm suitability and rule out contraindications
• Receive a prescription for a specific cannabis-based product

NHS prescribing remains exceptionally limited. Only a handful of NHS trusts offer medical cannabis prescriptions, with most prescriptions issued privately.

Private Prescribing and Costs

Private clinics and telemedicine services now offer medical cannabis consultations and prescriptions across the UK. Costs vary considerably.

Consultation fees typically range from £150 to £400 for an initial assessment. Follow-up appointments usually cost £100 to £250. Prescriptions themselves incur additional pharmacist and dispensing fees.

Medication costs depend on the product chosen. CBD-dominant oils or topicals might cost £15 to £60 monthly, whilst balanced THC/CBD preparations cost £50 to £150 monthly or more. Higher-potency products naturally command premium prices.

Private insurance rarely covers medical cannabis, making costs a significant barrier for many patients. Those pursuing private treatment should budget £300 to £800 for initial consultation and first month’s treatment, with ongoing monthly costs varying based on product strength and format.

Safety and Considerations

Medical cannabis carries risks and contraindications. Patients with a personal or family history of psychosis should avoid THC-containing products. Those taking blood thinners, sedatives, or immunosuppressants require careful monitoring due to potential drug interactions. Pregnancy and breastfeeding contraindicate use.

Common side effects include dry mouth, fatigue, and appetite changes. Regular monitoring from a prescribing specialist ensures safety and allows dose adjustments when needed.

Future Outlook

The medical cannabis landscape in the UK continues evolving. Ongoing clinical trials may expand evidence, potentially widening access and NHS availability. Patients considering this option should stay informed and consult with specialists experienced in cannabis prescribing.

Medical Cannabis UK | How to Get a Cannabis Prescription